查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2013027

抗癌药物市场：2026-2032 年全球市场预测，按药物类型、给药途径、治疗方法、癌症类型、最终用户和分销管道划分。

Cancer Drugs Market by Drug Type, Administration Route, Therapy Type, Cancer Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年癌症治疗市场价值为1,720.6亿美元，预计到2026年将成长至1,887.2亿美元，复合年增长率为10.13%，到2032年将达到3,382.9亿美元。

主要市场统计数据
基准年 2025 1720.6亿美元
预计年份：2026年 1887.2亿美元
预测年份 2032 3382.9亿美元
复合年增长率 (%) 10.13%

我们将着眼于根本驱动因素、新兴创新和策略性产业挑战，为癌症药物分析奠定基础。

癌症治疗的发展极为复杂，需要扎实的理论基础来概述肿瘤学领域的基本要素。对过往突破性进展的多方面理解，为解读当前化疗、标靶治疗和免疫调节剂领域的进展提供了必要的背景知识。本文以历史里程碑为基础，阐述了不断增长的研究经费、不断完善的监管途径以及以患者为中心的医疗模式如何相互交织，共同影响着当今的治疗重点。

技术突破和不断发展的患者照护模式正在推动癌症药物研发发生决定性变革。

过去十年，肿瘤治疗领域发生了翻天覆地的变化，这主要得益于免疫肿瘤学和分子标靶治疗的突破性进展。查核点抑制剂重塑了多种癌症的治疗流程，促使标准疗法和联合治疗的重新设计。同时，嵌合体抗原受体T细胞疗法也完成了从实验性治疗方法到商业性化应用的转变，开启了个人化免疫疗法的新时代。

评估美国新加征关税对癌症治疗供应链、价格趋势和全球竞争平衡的影响。

美国于2025年初实施的新关税为癌症治疗价值链上的所有相关人员带来了巨大挑战。采购和分销合作伙伴面临关键活性药物成分成本上涨的困境，这些成分均来自全球供应商，迫使他们重新评估製造地。近几个月来，一些机构已采取应对措施，包括供应商多元化、投资近岸外包以及重新谈判长期合同，以降低关税风险并防止药品供应中断。

揭示药物类别、给药途径、治疗方法、癌症适应症、最终用户画像和分销网络等方面的关键细分见解。

对治疗分类及其子类别的详细分析，能够清楚揭示抗癌药物市场的现状。化疗仍然是核心治疗方法，其中烷化剂、抗代谢药物和抗肿瘤抗生素在肿瘤清除方面各有其疗效和安全性方面的考虑。除了传统的细胞毒性药物外，免疫治疗领域也涌现了查核点抑制剂和CAR-T疗法，所有这些疗法都需要专门的给药方案和病患监测。

探讨美洲、欧洲、中东、非洲和亚太地区肿瘤市场的区域趋势和差异化市场驱动因素。

区域差异透过医疗基础设施、监管环境和报销机制的差异，影响癌症治疗的部署和推广。在美洲，成熟的专科药局网路与大型研究中心相辅相成，推动了先进治疗方法的广泛应用。北美领先的医疗中心正与支付方合作，开发创新的报销方案，在降低前期成本的同时，将治疗效果与价值挂钩。

揭示构成癌症药物生态系统的主要企业的策略性倡议、合作计画和创新组合。

为适应不断变化的癌症治疗格局，关键产业相关人员已重新评估其策略重点。领先的创新企业正增加对早期药物研发专案和后期临床试验的投资，以建立广泛的免疫肿瘤学产品线并实现产品组合多元化。生物技术公司与大型製药公司之间的合作正在加速，从而实现风险分散，并透过转授许可和共同开发契约授权合约利用彼此的专业知识。

为行业领导者提供策略挑战和可操作的建议，以利用新兴机会并应对肿瘤市场的复杂性。

产业领导者应优先考虑建构整合的研发框架，将药物发现、转化研究和临床应用连接起来，以加速从概念到商业化的进程。建立一个汇集药物化学、生物标记分析和监管框架等领域专业知识的跨职能卓越中心，可以简化决策流程并缩短研发週期。同时，与诊断服务提供者建立策略伙伴关係，能够共同开发伴随检测方法，从而优化个人化治疗方案。

全面阐述支持癌症药物研究的严格调查方法、资料收集方案和分析框架。

为确保分析的稳健性，本研究采用多方面的调查方法，整合了全面的二手资料研究、专家访谈以及严谨的资料三角验证。透过对同行评审期刊、监管指南和临床试验註册库的广泛文献回顾，我们得以深入了解治疗方法的进展。同时，我们也分析了专有资料库和产业期刊，以掌握竞争格局和专利趋势。

整合关键发现、产业影响和未来展望，以推动癌症治疗创新持续进步。

本篇综述整合了多项关键研究成果，重点阐述了免疫肿瘤学、精准医疗工具以及数位医疗融合领域的突破性进展如何共同重塑癌症治疗模式。新贸易政策的累积影响凸显了建立具有韧性的供应链和创新报销策略的必要性，以保障患者获得治疗的机会并确保商业性可行性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：按药物类型分類的抗癌药物市场

  • 化疗
    • 烷化剂
    • 抗代谢物
    • 抗肿瘤抗生素
  • 荷尔蒙疗法
  • 免疫疗法
  • 分子标靶治疗
    • 诱导细胞凋亡的药物
    • 单株抗体
    • 蛋白酪氨酸激酶抑制剂（TKIs）

第九章：抗癌药物市场依给药途径划分

  • 肌肉内部
  • 静脉
  • 口服
  • 皮下

第十章：依治疗方法分類的抗癌药物市场

  • 联合治疗
  • 单药治疗

第十一章：以癌症类型分類的抗癌药物市场

  • 乳癌
  • 结肠癌
  • 肝癌
  • 肺癌
  • 胰臟癌
  • 摄护腺癌

第十二章：抗癌药物市场：依最终用户划分

  • 门诊部
  • 家庭医疗保健
  • 医院和诊所

第十三章：抗癌药物市场：依通路划分

  • 医院药房
  • 零售药房

第十四章：抗癌药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：抗癌药物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：抗癌药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国抗癌药物市场

第十八章：中国抗癌药物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Getwell Oncology Pvt Ltd
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Kite Pharma, Inc by Gilead Company
  • Medivir AB
  • Merck & Co., Inc.
  • Nammi Therapeutics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-431B7BFFBF7B

The Cancer Drugs Market was valued at USD 172.06 billion in 2025 and is projected to grow to USD 188.72 billion in 2026, with a CAGR of 10.13%, reaching USD 338.29 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 172.06 billion
Estimated Year [2026] USD 188.72 billion
Forecast Year [2032] USD 338.29 billion
CAGR (%) 10.13%

Establishing the Foundation of Cancer Drug Analysis by Highlighting Fundamental Drivers, Emerging Innovations, and Strategic Industry Imperatives

The complexity of cancer drug development demands a well-grounded introduction that outlines the fundamental forces shaping the oncology therapeutic sphere. A nuanced understanding of past breakthroughs provides essential context for interpreting ongoing advancements in chemotherapies, targeted approaches, and immunomodulatory agents. Building from historical milestones, this introduction illuminates how intensified research funding, expanded regulatory pathways, and patient-centric care models converge to influence contemporary priorities.

Moreover, rapid technological evolution in molecular diagnostics and biomarker discovery has created new opportunities for precision oncology, driving collaboration among academic institutions, biotech startups, and established pharmaceutical developers. In this light, the introduction establishes a framework for how shifting regulatory paradigms-such as accelerated approval programs and adaptive licensing-facilitate the entry of innovative compounds while ensuring patient safety.

By setting the stage with key research enablers, stakeholder motivations, and cross-sector partnerships, this section underscores the dynamic environment in which oncology stakeholders operate. It paves the way for subsequent analysis of disruptive trends and market-shaping events, providing readers with a cohesive starting point to appreciate the deeper insights that follow.

Navigating the Pivotal Transformations in Oncology Drug Development Driven by Technological Breakthroughs and Evolving Patient Care Paradigms

Over the past decade, transformative shifts have redefined the oncology therapeutics landscape, driven by breakthroughs in immuno-oncology and molecularly targeted treatments. Checkpoint inhibitors have reshaped therapeutic algorithms across multiple cancer types, prompting redesigns of standard of care and combination regimens. Simultaneously, chimeric antigen receptor T cell therapies have crossed thresholds from experimental modalities to commercial realities, heralding a new era of personalized immunotherapy.

In parallel, the convergence of big data analytics and precision medicine tools has accelerated the identification of patient subpopulations most likely to benefit from specific interventions. This evolution has compelled industry leaders to integrate companion diagnostics into clinical development plans, fostering collaborative models between diagnostic and therapeutic stakeholders. Moreover, digital health platforms now support remote monitoring and real-time outcome tracking, enhancing trial efficiency and enabling adaptive trial designs that reduce development timelines.

As regulatory bodies refine frameworks for advanced therapies, the industry adapts by forging strategic alliances, expanding manufacturing capabilities, and integrating artificial intelligence for compound discovery. These advances underscore an ongoing paradigm shift that elevates efficacy, safety, and patient-centricity at the heart of oncology R&D.

Assessing the Ramifications of Newly Implemented United States Tariffs on Cancer Drug Supply Chains, Pricing Dynamics, and Global Competitive Equilibrium

The implementation of new United States tariffs in early 2025 has introduced significant headwinds for stakeholders across the cancer drug value chain. Procurement and distribution partners are facing increased costs for critical active pharmaceutical ingredients sourced from global suppliers, prompting a reassessment of manufacturing footprints. In recent months, several organizations have responded by diversifying supplier bases, investing in nearshoring initiatives, and renegotiating long-term contracts to mitigate tariff exposure and secure uninterrupted drug availability.

Furthermore, heightened import duties on specialized components have compelled pharmaceutical companies to adjust pricing frameworks, which in turn places pressure on reimbursement dialogues with payers. Payer panels and health technology assessment bodies are closely monitoring these cost adjustments, leading some manufacturers to pursue risk-sharing agreements and performance-based contracts to sustain market access.

Transitioning beyond immediate cost considerations, industry participants are also reevaluating supply chain resilience by integrating advanced analytics for demand forecasting and inventory management. These strategic shifts underscore the multifaceted impact of tariff introductions, demonstrating how regulatory trade actions can cascade through production, pricing, and patient access, ultimately reshaping competitive dynamics in oncology drug markets.

Unraveling Critical Segmentation Insights across Drug Classes, Administration Pathways, Therapy Modalities, Cancer Indications, End User Profiles, and Distribution Networks

Insight into the oncology drug market emerges clearly when dissecting therapeutic classes alongside their respective subcategories. Chemotherapy remains a cornerstone modality, with alkylating agents, antimetabolites, and antitumor antibiotics demonstrating differentiated efficacy profiles and safety considerations in tumor eradication. Beyond traditional cytotoxics, the immunotherapy cohort has introduced checkpoint inhibitors and CAR-T treatments, each requiring specialized administration protocols and patient monitoring.

Administration routes further refine market understanding by highlighting patient convenience and adherence factors. Intravenous infusions dominate hospital settings, whereas oral formulations offer greater flexibility for outpatient management and home healthcare delivery. Intramuscular and subcutaneous injections occupy niche roles in maintenance therapies and prophylactic regimens, reflecting a balance between therapeutic intent and patient experience.

Therapy type segmentation, distinguishing combination regimens from monotherapy approaches, reveals evolving clinical strategies aimed at overcoming resistance and enhancing synergistic effects. Cancer type delineation uncovers unique demand patterns across breast, colorectal, liver, lung, pancreatic, and prostate cancer cohorts, each presenting distinct molecular targets and treatment pathways.

End user segmentation clarifies distribution of care delivery, from hospitals and clinics as centralized hubs to ambulatory care centers and home healthcare solutions that prioritize patient comfort. Distribution channel analysis underscores the roles of hospital pharmacies in inpatient settings and retail pharmacies in broadening access for maintenance therapies.

Exploring Regional Dynamics and Differentiated Market Drivers across the Americas, Europe Middle East and Africa, and the Asia Pacific Oncology Landscapes

Regional landscapes shape the deployment and adoption of cancer therapeutics through variations in healthcare infrastructure, regulatory environments, and reimbursement mechanisms. In the Americas, well-established specialty pharmacy networks complement leading research centers, driving robust uptake of advanced therapies. North American centers of excellence collaborate with payers to structure innovative reimbursement schemes that mitigate upfront costs and link outcomes to value.

Moving eastward, the Europe, Middle East, and Africa region presents a tapestry of regulatory frameworks. While Western European nations lean on centralized approval pathways and stringent health technology assessments, Middle Eastern markets are investing heavily in oncology infrastructure and forging public-private partnerships to expand access. African markets continue to build foundational oncology programs, with an increasing focus on affordable generics and biosimilars to bridge treatment gaps.

Across the Asia-Pacific domain, diverse economies drive heterogenous demand patterns. Advanced markets such as Japan and Australia leverage strong R&D ecosystems and integrated care models, while emerging economies prioritize capacity building in oncology centers and localization of manufacturing. Regional harmonization efforts aim to streamline regulatory submissions, accelerating the entry of novel agents into clinical practice and supporting patient-centric care models.

Illuminating Strategic Moves, Collaborative Endeavors, and Innovation Portfolios of Leading Entities Shaping the Cancer Therapeutics Ecosystem

Key industry participants have recalibrated their strategic priorities to align with the evolving oncology therapeutic environment. Leading innovators have pursued expansive immuno-oncology pipelines, investing in both early-stage discovery programs and late-stage clinical trials to diversify their portfolios. Collaboration between biotechs and major pharmaceutical firms has accelerated, enabling sublicensing deals and co-development agreements that distribute risk and leverage complementary expertise.

Manufacturers with robust biologics infrastructure are expanding capacity for cell and gene therapies, preempting anticipated manufacturing bottlenecks. Simultaneously, the emergence of digital health partnerships has allowed select companies to integrate real-world evidence collection into their launch strategies, enhancing post-market value propositions. Players with global regulatory experience are optimizing dossier submissions to navigate complex approval pathways, particularly in regions adopting novel regulatory paradigms.

Smaller specialized firms are capitalizing on niche targets, forging alliances to secure co-marketing opportunities and expand trial networks. Across the competitive landscape, agility and scientific differentiation have emerged as critical differentiators, enabling companies to position their assets effectively against established standards of care and pipeline entrants.

Strategic Imperatives and Pragmatic Recommendations for Industry Leaders to Capitalize on Emerging Opportunities and Navigate Oncology Market Complexities

Industry leaders should prioritize integrated R&D frameworks that bridge discovery, translational research, and clinical application to accelerate the path from concept to commercialization. Establishing cross-functional centers of excellence that coalesce medicinal chemistry, biomarker analytics, and regulatory expertise can streamline decision making and reduce development timelines. In parallel, forging strategic alliances with diagnostics providers will enable the co-development of companion assays that bolster personalized treatment protocols.

To mitigate supply chain vulnerabilities exposed by recent trade policy shifts, organizations must diversify sourcing strategies and invest in advanced supply planning platforms. Scenario modeling and digital twins for logistics networks can empower procurement teams to anticipate disruptions and maintain consistent access to high-value active pharmaceutical ingredients. Moreover, engaging payers early to define outcome-based reimbursement frameworks will align commercial strategies with therapeutic value and ensure sustained market access.

Finally, embedding patient-centricity through digital support services and telehealth integration can enhance adherence, real-world data capture, and long-term outcomes tracking. By adopting these recommendations, industry players can fortify their competitive positioning and lead in delivering next-generation oncology treatments.

Comprehensive Elucidation of Rigorous Research Methodologies, Data Collection Protocols, and Analytical Frameworks Underpinning the Oncology Drug Study

This research employs a multifaceted methodology that integrates exhaustive secondary research, primary expert interviews, and rigorous data triangulation to ensure analytical robustness. Extensive literature reviews of peer-reviewed journals, regulatory guidelines, and clinical trial registries provided a foundational understanding of therapeutic advancements. Concurrently, proprietary databases and industry publications were analyzed to map competitive activity and patent landscapes.

Primary insights were garnered through structured interviews with senior executives, clinical investigators, and reimbursement specialists, yielding firsthand perspectives on pipeline strategies, market access barriers, and patient needs. Quantitative and qualitative findings were cross-validated through triangulation techniques, ensuring consistency across data sources and minimizing bias.

Furthermore, the study incorporated scenario analyses to examine the impact of policy shifts, such as tariff implementations, on production and distribution dynamics. Ethical adherence to data privacy and confidentiality standards was maintained throughout. The resulting framework synthesizes complex inputs into a coherent narrative, furnishing stakeholders with actionable intelligence underpinned by transparent methodologies.

Synthesis of Core Findings, Industry Implications, and Forward-Looking Perspectives to Propel Continued Advancements in Cancer Drug Innovation

In synthesizing the core findings, the review underscores how immuno-oncology breakthroughs, precision medicine tools, and digital health integrations collectively redefine the cancer treatment paradigm. The cumulative effects of new trade policies highlight the necessity for resilient supply chains and innovative reimbursement strategies to preserve patient access and commercial viability.

Segmentation analyses clarify nuanced demand drivers across therapeutic classes, administration modes, and care settings, while regional insights reveal differentiated growth enablers shaped by regulatory and infrastructure variances. The competitive landscape analysis illustrates that collaborative alliances and agile portfolio management are essential for maintaining differentiation in a crowded pipeline.

Looking forward, the interplay between scientific innovation, regulatory evolution, and patient-centric frameworks promises to sustain momentum in oncology drug development. Stakeholders who embrace integrated research models, engage with payers on value-based approaches, and invest in resilient operational infrastructures will be best positioned to deliver transformative therapies and secure long-term market leadership.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Drugs Market, by Drug Type

  • 8.1. Chemotherapy
    • 8.1.1. Alkylating Agents
    • 8.1.2. Antimetabolites
    • 8.1.3. Antitumor Antibiotics
  • 8.2. Hormone Therapy
  • 8.3. Immunotherapy
  • 8.4. Targeted Therapy
    • 8.4.1. Apoptosis-inducing Drugs
    • 8.4.2. Monoclonal Antibodies
    • 8.4.3. Tyrosine Kinase Inhibitors (TKIs)

9. Cancer Drugs Market, by Administration Route

  • 9.1. Intramuscular
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous

10. Cancer Drugs Market, by Therapy Type

  • 10.1. Combination Therapy
  • 10.2. Monotherapy

11. Cancer Drugs Market, by Cancer Type

  • 11.1. Breast Cancer
  • 11.2. Colorectal Cancer
  • 11.3. Liver Cancer
  • 11.4. Lung Cancer
  • 11.5. Pancreatic Cancer
  • 11.6. Prostate Cancer

12. Cancer Drugs Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Home Healthcare
  • 12.3. Hospitals & Clinics

13. Cancer Drugs Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Retail Pharmacy

14. Cancer Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cancer Drugs Market

18. China Cancer Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Amgen Inc.
  • 19.7. Astellas Pharma Inc
  • 19.8. AstraZeneca PLC
  • 19.9. Bayer AG
  • 19.10. BeiGene, Ltd.
  • 19.11. Bristol-Myers Squibb Company
  • 19.12. Daiichi Sankyo Company, Limited
  • 19.13. Dr. Reddy's Laboratories Ltd.
  • 19.14. Eli Lilly and Company
  • 19.15. F. Hoffmann-La Roche Ltd
  • 19.16. Fresenius Kabi AG
  • 19.17. Getwell Oncology Pvt Ltd
  • 19.18. GlaxoSmithKline plc
  • 19.19. Incyte Corporation
  • 19.20. Kite Pharma, Inc by Gilead Company
  • 19.21. Medivir AB
  • 19.22. Merck & Co., Inc.
  • 19.23. Nammi Therapeutics, Inc.
  • 19.24. Novartis AG
  • 19.25. Pfizer Inc.
  • 19.26. Sanofi S.A.
  • 19.27. Sun Pharmaceutical Industries Ltd.
  • 19.28. Taiho Pharmaceutical Co., Ltd. by Otsuka Holdings Co., Ltd.
  • 19.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER DRUGS MARKET SIZE, BY ANTITUMOR ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER DRUGS MARKET SIZE, BY APOPTOSIS-INDUCING DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS (TKIS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER DRUGS MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GCC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. GCC CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. GCC CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. GCC CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. GCC CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. GCC CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. G7 CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. G7 CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 204. G7 CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 206. G7 CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. G7 CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. G7 CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. NATO CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. NATO CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. NATO CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. NATO CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA CANCER DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA CANCER DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA CANCER DRUGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA CANCER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)